GenEp is a technology company.
GenEp has raised $1.0M across 1 funding round.
GenEp has raised $1.0M in total across 1 funding round.
GenEp has raised $1.0M in total across 1 funding round.
GenEp's investors include 3B Future Health Ventures (Helsinn Investment Fund).
GenEp is a pre-clinical stage biotechnology company developing therapies for rare genetic epilepsies and treatment-resistant epilepsies by targeting mutations in sodium and other ion channels. Founded in 2021 in Charlottesville, Virginia, it licenses intellectual property from the University of Virginia and has raised approximately $10.41M in seed funding, including a $4M round six months ago.[1][2][3] The company serves patients with unmet needs in epilepsy, particularly pediatric cases like SCN8A epileptic encephalopathy, using proprietary tools such as the mouse audiogenic reflex seizure model (MARS™) for rapid in vivo screening of CNS-selective sodium channel modulators like Nav1.6 and Nav1.2.[3][6] Its growth momentum includes multiple seed rounds from investors like UVA Licensing & Ventures Group, Angelini Lumira Biosciences Fund, and 3B Future Health Fund, supporting advancement toward first-in-class treatments.[1][3][6]
GenEp emerged from University of Virginia researcher Manoj Patel's intellectual property portfolio on ion channel mutations driving epilepsy, licensed through UVA Licensing & Ventures Group.[2][4] The company was founded in 2021 as the second UVA startup from the LVG Entrepreneurs in Residence program, with Andrew Krouse joining as CEO and President to lead operations.[2][4][6] Krouse's team brings experience from Cavion, previously acquired by Jazz Pharmaceuticals in 2019, providing pivotal expertise in epilepsy drug development.[6] Early traction came swiftly with a $1.45M seed financing in October 2021, co-led by UVA LVG Seed Fund, Angelini Lumira Biosciences Fund, and 3B Future Health Fund, fueling initial development of selective sodium channel therapies.[3][6]
GenEp rides the wave of precision medicine in neurology, targeting ion channelopathies amid rising demand for genetic therapies in rare epilepsies affecting ~1% of the global population, where 30% remain drug-resistant.[2][6] Timing aligns with advances in gene sequencing and CRISPR-enabled target validation, enabling faster drug discovery for pediatric rare diseases qualifying for FDA incentives like orphan drug status.[5][6] Market forces favor it through growing VC interest in biotech (e.g., seed rounds tripling in neuro-focused firms post-2020) and partnerships with academic licensors like UVA, which accelerate translation from lab to clinic.[1][2] GenEp influences the ecosystem by validating UVA's startup model and contributing to the epilepsy pipeline, potentially reducing the $15B+ annual U.S. epilepsy burden via innovative screening that de-risks candidates for big pharma acquisition.[3][6]
GenEp's next milestones likely include IND-enabling studies and Phase 1 trials within 2-3 years, leveraging its $10M+ runway and MARS™ model to nominate leads for SCN8A and related indications.[3][6] Trends like AI-accelerated screening and expanded orphan drug funding will propel its trajectory, while partnerships with Jazz-like acquirers could mirror Cavion's exit. Its influence may grow by pioneering ion channel precision therapies, solidifying Charlottesville as a neuro-biotech hub and delivering hope for epilepsy families—echoing its mission to transform rare disease outcomes from the UVA innovation roots.
GenEp has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $1.0M Seed | 3B Future Health Ventures (Helsinn Investment Fund) |